Navigation Links
PegIFN-lambda shows superior virological response and improved safety than PegIFN-alpha-2a
Date:4/2/2011

Berlin, Germany, 02 April 2011: Highly exciting new data presented today at the International Liver CongressTM found Pegylated Interferon-lambda (PegIFN-lambda) shows superior virological response in HCV patients of genotypes 1-4, with improved safety and tolerability, compared to Pegylated Interferon-alpha (PegIFN-alpha-2a), the current standard of care in chronic HCV.1

The study results are so important because they show PegIFN-lambda could provide relief for the 20% of HCV patients who have to undergo dose reduction, or cease treatment, on PegIFN-alpha-2a a part of the current HCV standard of care.2

The trial shows that PegIFN-lambda provides higher rapid virological response (RVR) and complete early virological response (cEVR) than PegIFN-alpha-2a, even in patients with an unfavourable IL28B genotype which predisposes patients to be resistant to treatment.

Both RVR and cEVR are important markers of a drug's ability to combat HCV infection: RVR is measured as undetectable HCV RNA at week 4 of therapy, maintained up to end of treatment; cEVR is detectable HCV RNA at week 4, but undetectable at week 12, maintained up to end of treatment.

Results at week 12 of the trial show that those HCV genotype 1 and 4 patients given 180g of PegIFN-lambda achieved RVR 14.7% of the time and cEVR 55.9% of time, compared to 5.8% RVR and 37.9% cEVR in patients given the same dose of PegIFN-alpha-2a.

The study also found PegIFN-lambda was associated with fewer hematologic (blood cell) toxicities, flu-like symptoms, musculoskeletal symptoms, dose reductions and premature discontinuations than the same dose of PegIFN-alpha-2a. However, in the higher dose groups elevations of ALT and bilirubin were observed which may represent drug related toxicity.

Professor Heiner Wedemeyer, EASL's Secretary General, commented: "These are clearly very early results but the combination of better virological response and fewer side effects makes these very exciting findings. The percentage of current HCV patients that have to cease treatment, or have their dose lowered, due to the side effects associated with PegIFN-alpha-2a is high. We look forward to seeing the sustained virological responses, which will inform us whether PegIFN-lambda could be used as a replacement for PegIFN-lambda in the future."

In the ongoing randomized phase-IIB trial, 526 treatment-nave HCV patients received ribavirin with weekly subcutaneous PegIFN-alpha-2a a 180g dose or PegIFN-lambda either a 120, 180 or 240g doses.

In HCV genotype 2 and 3 patients, 180g of PegIFN-lambda led to 75.9% RVR and 96.6% cEVR, compared to 31% RVR and 86.2% cEVR for the same dose of PegIFNα-2a. PegIFN-lambda exerts its antiviral effects through a different receptor to PegIFN-alpha-2a.1


'/>"/>

Contact: Travis Taylor
easlpressoffice@cohnwolfe.com
44-784-306-9451
European Association for the Study of the Liver
Source:Eurekalert

Related medicine news :

1. First blinded study of venous insufficiency prevalence in MS shows promising results
2. People with anxiety disorder less able to regulate response to negative emotions, study shows
3. Poll Shows Eroding Support for Health Reform
4. Protecting patients: Study shows that Johns Hopkins flu vaccination rates twice national average
5. Compound shows promise against intractable heart failure
6. Drama or reality TV: Do medical shows depict proper first aid for seizures?
7. TV Shows Often Botch Proper Seizure Responses
8. UQ research shows canecutters disease on the rise among travelers
9. Brain Scan Shows What Beauty is Worth
10. Untreated poor vision in elderly linked to dementia, University of Michigan study shows
11. New research shows emotional impact of low sexual desire and associated distress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... 10, 2016 , ... Intermedix announced on Wednesday that it ... emergency medicine professional association, to support the organization's newly established physician group with ... Emergency Medicine, or AAEM, seeks to empower emergency physicians to control their own ...
(Date:2/10/2016)... ... February 10, 2016 , ... The Wickman Agency ... to assist the local community. Pledging to select a new beneficiary every 60 ... the area. Their goal is to bring community awareness to important local causes ...
(Date:2/10/2016)... ... February 10, 2016 , ... 10 Best Water is excited ... bottled water brand owners that topped the list as a result of their commitment ... The premier brand was Tibet 5100, a top notch water company that specializes in ...
(Date:2/10/2016)... ... 10, 2016 , ... Dr. Jessica Barron, of Barron Family Dental in ... patients and families in the North Metro Denver area. The new dental practice focuses ... dentistry, and all in the most relaxing environment. , While some dental visits can ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... bring together more than 200 of the country’s top healthcare executives to share ... “The true benefit of the Forum is the provider-centric perspective, experience, expertise and ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... Inc. (Vanda) (NASDAQ: VNDA ), today announced financial ... year ended December 31, 2015. --> ... for Vanda with the continued growth of HETLIOZ in ... for Non-24," said Mihael H. Polymeropoulos, M.D., Vanda,s President ... product portfolio builds on this success and underscores Vanda,s ...
(Date:2/10/2016)... new report from business intelligence provider GBI Research - Alzheimer,s Disease Therapeutics ... than double from just under $5 billion in 2014 to an estimated $10.4 ... Canada , France , Germany ... UK, and Japan , and will primarily be driven by ... , France , Germany , ...
(Date:2/10/2016)...  CVS Health (NYSE: CVS ) is offering ... Santa Clara County, CA , in response to ... University campus. CVS Pharmacy stores and MinuteClinic walk-in medical ... disease. Students at Santa Clara University who have not ... anyone who has had close contact with a person ...
Breaking Medicine Technology: